Table 1.
Baseline demographics and disease characteristics
| Parameter, mean (SD)a | Baseline biologic experience | Baseline TCZ treatment | All patients n = 1912 | ||
|---|---|---|---|---|---|
| Biologic naïve n = 1073 | Biologic exposed n = 839 | TCZ monotherapy n = 639 | TCZ combination therapy n = 1273 | ||
| Age, years | 51.7 (13.4) | 54.9 (13.3) | 54.5 (13.3) | 52.4 (13.4) | 53.1 (13.4) |
| Female, n (%) | 881 (82.2) | 698 (83.2) | 512 (80.3) | 1067 (83.8) | 1579 (82.6) |
| Male, n (%) | 191 (17.8) | 141 (16.8) | 126 (19.7) | 206 (16.2) | 332 (17.4) |
| Duration of RA, years | 6.9 (7.4) | 11.4 (9.9) | 9.7 (10.0) | 8.5 (8.3) | 8.9 (8.9) |
| Duration of TCZ treatment, days | 176.8 (74.9) | 212.1 (88.5) | 188.5 (83.9) | 194.2 (82.5) | 192.3 (83.0) |
| Patient assessment of RA pain on VAS, mm | 62.3 (23.0) | 64.2 (22.4) | 63.6 (22.6) | 63.0 (22.9) | 63.2 (22.8) |
| Patient assessment of disease activity on VAS, mm | 63.4 (22.7) | 66.1 (21.7) | 65.6 (21.0) | 64.2 (22.8) | 64.6 (22.2) |
| Patient assessment of fatigue on VAS, mm | 57.3 (26.2) | 63.0 (24.0) | 59.2 (25.2) | 59.7 (25.7) | 59.6 (25.5) |
| Patient assessment of morning stiffness on VAS, mm | 54.0 (27.8) | 58.3 (26.1) | 56.4 (26.0) | 55.5 (27.7) | 55.8 (27.2) |
| Patients with morning stiffness, n (%) | 763 (91.9) | 605 (92.8) | 424 (92.0) | 944 (92.5) | 1368 (92.3) |
| Physician assessment of disease activity on VAS, mm | 58.9 (22.1) | 60.4 (21.4) | 58.2 (22.6) | 60.2 (21.4) | 59.6 (21.8) |
| HAQ-DIb | 1.6 (0.8) | 1.6 (0.7) | 1.6 (0.8) | 1.6 (0.8) | 1.6 (0.8) |
| DAS28c | 6.0 (1.3) | 5.7 (1.2) | 5.7 (1.3) | 5.9 (1.2) | 5.8 (1.2) |
| CDAI | 33.6 (14.7) | 32.2 (13.4) | 31.8 (14.1) | 33.7 (14.3) | 33.1 (14.2) |
| SDAI | 36.9 (16.2) | 34.6 (14.2) | 34.3 (15.4) | 36.6 (15.4) | 35.9 (15.4) |
| TJC28 | 12.5 (7.7) | 11.4 (7.3) | 11.0 (7.4) | 12.5 (7.6) | 12.0 (7.5) |
| SJC28 | 8.8 (6.6) | 7.3 (5.8) | 7.6 (6.1) | 8.4 (6.3) | 8.1 (6.3) |
| ESR, mm/h | 45.9 (31.9) | 36.3 (26.3) | 41.2 (30.6) | 42.1 (29.7) | 41.8 (30.0) |
| CRP, mg/l | 30.7 (47.3) | 22.1 (29.3) | 24.8 (35.6) | 27.9 (42.8) | 26.9 (40.6) |
CDAI clinical disease activity index, CRP C-reactive protein, DAS28 Disease Activity Score using 28 joints, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, SDAI simplified disease activity index, SJC28 swollen joint count at 28 joints, TCZ tocilizumab, TJC28 tender joint count at 28 joints, VAS visual analog scale
aExcept where otherwise indicated
bHAQ-DI data from Belgian patients were excluded because of use of an alternative scoring system
cDAS28-ESR or, if missing, DAS28-CRP